CDC Superbug Report Counts a Crisis Hiding in Plain Sight

The CDC superbug report, released Tuesday, puts a stark number on a threat that rarely makes headlines. Drug-resistant germs cause an estimated 9.7 million infections in the United States each year and 50,800 deaths, according to the Centers for Disease Control and Prevention. The report is the agency's first full update since the previous edition, and it carries a blunt message: the medicines that make modern health care possible are losing ground to germs that learn to survive them.

That last point deserves more attention than it usually gets. Antibiotics are the quiet foundation under much of routine medicine. Joint replacements, organ transplants, and cancer therapy all depend on drugs that can stop an infection before it takes hold, and so does long-term care for chronic conditions such as diabetes and asthma. When those drugs fail, a routine operation can turn into a prolonged hospital stay, and a treatable infection can become a life-threatening one. The CDC superbug report frames resistance as a threat to that foundation, not as a footnote to it. Globally, resistant infections kill over a million people a year, according to the agency, which makes the CDC superbug report a domestic snapshot of a much wider pattern.

Four threats at the top of the list

The CDC superbug report sorts nineteen pathogens into three tiers: urgent, serious, and concerning. Four germs sit in the urgent tier, the category reserved for threats that demand aggressive action. They are Candida auris, a fungus that spreads inside health care facilities; carbapenem-resistant Acinetobacter; carbapenem-resistant Enterobacterales; and drug-resistant gonorrhea. Thirteen more threats land in the serious tier, including MRSA and drug-resistant tuberculosis, while two sit in the concerning tier.

Candida auris stands out in the new data. Cases of the fungus have risen roughly tenfold since the last report, and some strains resist nearly every antifungal drug available. The report also flags the rapid spread of resistance genes, fragments of genetic code that let bacteria pass drug-defeating traits to each other. Once those genes take hold in a hospital ward, infections that once responded to standard treatment can stop responding altogether, leaving doctors with fewer options and patients with longer, riskier recoveries.

Where prevention already worked

The report is not uniformly grim. Clostridioides difficile, a bacterium that causes severe diarrhea, moved down from the urgent tier to the serious tier after infection rates fell and stayed lower, a shift the CDC credits in part to stronger infection prevention inside health care settings. That change matters because it shows the other side of the ledger: when hospitals tighten hygiene, testing, and antibiotic stewardship, resistant threats can retreat. Drug-resistant Neisseria meningitidis joined the serious tier as a new addition, and the agency added a watch list of six pathogens whose full burden is not yet understood, including drug-resistant dermatophytes and nontuberculous mycobacteria.

One caution runs through the CDC superbug report. The figures draw on data from 2023, and the agency updated its data sources and methods so thoroughly that officials caution against comparing the new totals directly with the previous edition. The jump in the headline numbers partly reflects better surveillance catching infections that earlier counts missed. That caveat does not soften the warning. It means the country is only now seeing the fuller shape of a problem that was already there.

Medical groups responding to the report called for stronger infection control, wider genomic surveillance, and financial incentives to revive antibiotic and antifungal development, including the PASTEUR Act proposal. The logic is straightforward: drug development has slowed because new antibiotics are used sparingly by design, which makes them poor commercial bets, while resistance keeps compounding in hospitals and communities. Without fresh drugs and faster detection, doctors face a shrinking toolkit against germs that keep adapting. The CDC superbug report gives that argument fresh numbers, and a deadline measured in infections rather than years.

The serious tier deserves a closer look, because it holds the infections most readers are likeliest to encounter. Alongside MRSA and drug-resistant tuberculosis, it includes vancomycin-resistant Enterococcus and drug-resistant strains of Salmonella and Shigella, germs tied to food poisoning and hospital stays alike. The concerning tier, the lowest rung, holds drug-resistant group A strep and clindamycin-resistant group B strep, both watched for signs they could climb higher in a future edition.

CDC Director Erica Schwartz put the stakes plainly in a statement announcing the report: “Antimicrobial resistance threatens modern medicine and puts millions of Americans at risk every year.” The report lands in a news cycle crowded with louder stories, and that is precisely why it belongs in the foreground. A crisis measured in millions of infections a year, unfolding quietly in wards and clinics, will not wait for a more convenient moment to be taken seriously.